Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity

被引：224
作者：
Gerhard, Danielle M. [1 ]
Wohleb, Eric S. [2 ]
Duman, Ronald S. [2 ]
机构：
[1] Yale Univ, Dept Psychol, New Haven, CT 06511 USA
[2] Yale Univ, Mol Psychiat, New Haven, CT 06711 USA
来源：
DRUG DISCOVERY TODAY | 2016年 / 21卷 / 03期
关键词：
METHYL-D-ASPARTATE; MEDIAL PREFRONTAL CORTEX; NMDA RECEPTOR BLOCKADE; PROOF-OF-CONCEPT; ANTIDEPRESSANT EFFICACY; PROTEIN EXPRESSION; MAJOR DEPRESSION; PARTIAL AGONIST; D-CYCLOSERINE; KETAMINE;
D O I：
10.1016/j.drudis.2016.01.016
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Major depression is a chronic and debilitating illness that effects approximately 1 in 5 people, but currently available treatments are limited by low rates of efficacy, therapeutic time lag, and undesirable side effects. Recent efforts have been directed towards investigating rapid-acting agents that reverse the behavioral and neuronal deficits of chronic stress and depression, notably the glutamate NMDA receptor antagonist ketamine. The cellular mechanisms underlying the rapid antidepressant actions of ketamine and related agents are discussed, as well as novel, selective glutamatergic receptor targets that are safer and have fewer side effects.
引用
收藏
页码：454 / 464
页数：11
相关论文
共 100 条
  • [71] Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test
    Palucha-Poniewiera, Agnieszka
    Pilc, Andrzej
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (01) : 102 - 106
  • [72] The BDNF Val66Met Polymorphism Impairs Synaptic Transmission and Plasticity in the Infralimbic Medial Prefrontal Cortex
    Pattwell, Siobhan S.
    Bath, Kevin G.
    Perez-Castro, Rosalia
    Lee, Francis S.
    Chao, Moses V.
    Ninan, Ipe
    [J]. JOURNAL OF NEUROSCIENCE, 2012, 32 (07) : 2410 - 2421
  • [73] Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent
    Preskorn, Sheldon
    Macaluso, Matthew
    Mehra, Vishaal
    Zammit, Gary
    Moskal, Joseph R.
    Burch, Ronald M.
    [J]. JOURNAL OF PSYCHIATRIC PRACTICE, 2015, 21 (02) : 140 - 149
  • [74] An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder
    Preskorn, Sheldon H.
    Baker, Bryan
    Kolluri, Sheela
    Menniti, Frank S.
    Krams, Michael
    Landen, Jaren W.
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (06) : 631 - 637
  • [75] Reddy M S, 2010, Indian J Psychol Med, V32, P1, DOI 10.4103/0253-7176.70510
  • [76] Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
    Sanacora, G.
    Smith, M. A.
    Pathak, S.
    Su, H-L
    Boeijinga, P. H.
    McCarthy, D. J.
    Quirk, M. C.
    [J]. MOLECULAR PSYCHIATRY, 2014, 19 (09) : 978 - 985
  • [77] Bipolar and major depressive disorder: Neuroimaging the develop mental-degenerative divide
    Savitz, Jonathan
    Drevets, Wayne C.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2009, 33 (05) : 699 - 771
  • [78] Peripheral BDNF Produces Antidepressant-Like Effects in Cellular and Behavioral Models
    Schmidt, Heath D.
    Duman, Ronald S.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2010, 35 (12) : 2378 - 2391
  • [79] Stress-induced dendritic remodeling in the medial prefrontal cortex: Effects of circuit, hormones and rest
    Shansky, Rebecca M.
    Morrison, John H.
    [J]. BRAIN RESEARCH, 2009, 1293 : 108 - 113
  • [80] EFFECT OF PHARMACOLOGICAL TREATMENTS ON THE SLEEP OF DEPRESSED-PATIENTS
    SHARPLEY, AL
    COWEN, PJ
    [J]. BIOLOGICAL PSYCHIATRY, 1995, 37 (02) : 85 - 98
12345678910